Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
TAUBER R;
FEUERECKER Benedikt;
KNORR Karina;
BEHESHTI A;
SEIDL C.;
BRUCHERTSEIFER Frank;
RETZ M;
WEBER Wolfgang;
GSCHWEND J.E.;
MORGENSTERN Alfred;
EIBER Matthias;
2020-03-03
SPRINGER HEIDELBERG
JRC116164
0340-2592 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116164,
10.1007/s00120-019-1018-y (online),
Additional supporting files
| File name | Description | File type | |
|---|
